Belite Bio (BLTE) said late Wednesday it signed a securities purchase deal with a new healthcare investor to buy and sell 258,309 of its American depositary shares and warrants to buy equal amount of American depositary shares at $58.07 per ADS in a registered direct offering for gross proceeds of roughly $15 million.
The biopharmaceutical company intends to close the offering around Friday, and plans to use the net proceeds for working capital and general corporate purposes, it added.
Belite Bio's stock was down more than 1% in recent Thursday premarket activity.
Price: 57.11, Change: -0.96, Percent Change: -1.65
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。